Mortality Predictors among COVID-19 Patients Admitted to the Intensive Care Unit in Sulaymaniyah City, Iraq: A Cross-Sectional Study

Alyaa Amer  Abdulla; Sherzad Ali  Ismael

doi:10.56056/amj.2024.282

Authors

Alyaa Amer Abdulla Kurdistan Board student of Community Medicine, Kurdistan Higher Council of Medical Specializations, Erbil, Iraq
Sherzad Ali Ismael Professor of Community Medicine, Kurdistan Higher Council of Medical Specializations, Erbil, Iraq

DOI:

https://doi.org/10.56056/amj.2024.282

Keywords:

Covid19, ICU, Iraq, Mortality Predictors, Sulaymaniyah

Abstract

Background and objectives: On February 22, 2020, Iraq confirmed the first case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The number of confirmed cases in Sulaimaniyah city reached 152,846, with 3,178 deaths. Our objective was to assess the clinical characteristics and identify variables that may predict mortality of COVID-19 cases in the intensive care unit.

Methods: Our cross-sectional study involved patients who were diagnosed with laboratory-confirmed Covid-19 and admitted to the intensive care unit of Shaheed Dr. Hemn Hospital/ Sulaymaniyah/ Iraqi Kurdistan from January 15, 2021, to April 29, 2022. Collected data included the patient's demographic characteristics, vital signs, hematological parameters, and management as documented in the patient's medical records. Patients were separated to two groups: those who were discharged and those who were dead. The binary logistic regression model was used to identify independent factors that predict mortality.

Results: During the study period, 403 patients were admitted to the intensive care unit. Case fatality rate was high 69.2%. The patient’s average age was 61.42 ±13.17 years, and 249 (61.8%) of them were men. The majority of the patients 319 (79.2%) had comorbidities. Lymphocytopenia was observed in 306 (75.9%) of the patients and there was a statistically significant difference between discharged and death groups (p value 0.021). Remdesivir was given to 185 patients (45.9%) and there was a statistically significant difference between discharged and death groups, p-value <0.001.

Conclusions: Critically ill patients with COVID-19 had a high mortality rate in the intensive care unit. low SBP, GCS<15, high D. dimer, and poor oxygen saturation were considered predictor factors of mortality.

Downloads

Download data is not yet available.

References

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727–33.

WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020.https://www.who.int/dg/speeches/detail/who-director-general-s-openingremarks-at-the-media-briefing-on-covid-19-11-March-2020 accessed 7 September 2022.

Johns Hopkins University. Coronavirus Resource Center. https:// coronavirus.jhu.edu/. Accessed on September 3, 2022.

Kiss S, Gede N, Hegyi P, Németh D, Földi M, Dembrovszky F, et al. Early changes in laboratory parameters are predictors of mortality and ICU admission in patients with COVID-19: a systematic review and meta-analysis. Med Microbiol Immunol. 2021;210(1):33-47. doi: 10.1007/s00430-020-00696-w. Epub 2020 Nov 21.

Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. doi: 10.1001/jama.2020.2648/

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet.2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5/

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 ;395(10229): 1054-62.doi: 10.1016/S0140-6736(20)30566-3/

Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81. doi: 10.1016/S2213-2600(20)30079-5/

Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-81. doi: 10.1001/jama.2020.5394/

Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020;382(21):2012-22. doi: 10.1056/NEJMoa2004500/

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9. doi:10.1001/jama.2020.6775/

Wang Y, Lu X, Li Y, Chen H, Chen T, Su N, et al. Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. Am J Respir Crit Care Med. 2020;201(11): 1430-4. doi: 10.1164/rccm.202003-0736LE/

Taccone FS, Van Goethem N, De Pauw R, Wittebole X, Blot K, Van Oyen H, et al. The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium. Lancet Reg Health Eur.2020;2: 100019. doi: 10.1016/j.lanepe.2020.100019/

World Health Organization. Clinical management of COVID-19: Living guideline, 2022.

Jain S, Iverson LM. Glasgow Coma Scale. 2022. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022–. PMID: 30020670.

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10. doi: 10.1001/jama.2016.0287/

San I, Gemcioglu E, Baser S, Yilmaz Cakmak N, Erden A, Izdes S, et al. Brescia-COVID Respiratory Severity Scale (BRCSS) and Quick SOFA (qSOFA) score are most useful in showing severity in COVID-19 patients. Sci Rep. 2021;11(1):21807. doi: 10.1038/s41598-021-01181-x/

Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors associated with death in critically ill patients with Coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180(11):1436-47. doi: 10.1001/jamainternmed.2020.3596/

Xie J, Wu W, Li S, Hu Y, Hu M, Li J, et al. Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study. Intensive Care Med. 2020;46(10):1863-72. doi: 10.1007/s00134-020-06211-2/

Jiménez-Ibáñez EO, Castillejos-López M, Hernández A, Gorocica P, Alvarado-Vásquez N. High mortality associated with hyperglycemia, neutrophilia, and lymphopenia in critically ill patients. Tohoku J Exp Med. 2012;226(3):213-20. doi: 10.1620/tjem.226.213/

Liu Q, Song NC, Zheng ZK, Li JS, Li SK. Laboratory findings and a combined multifactorial approach to predict death in critically ill patients with COVID-19: a retrospective study. Epidemiol Infect. 2020;148. doi: 10.1017/S0950268820001442/

Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, et al. Prognostic value of C-reactive protein in patients with Coronavirus 2019. Clin Infect Dis. 2020;71(16):2174-79. doi: 10.1093/cid/ciaa641/

Tharakan S, Nomoto K, Miyashita S, Ishikawa K. Body temperature correlates with mortality in COVID-19 patients. Crit Care 24. 2020;24(1):1-3. doi.org/10.1186/s13054-020-03045-8/

Norman DC. Fever in the elderly. Clin Infect Dis. 2000;31(1):148-51. doi: 10.1086/313896/

Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020;323(16):1612-14. doi: 10.1001/jama.2020.4326/

Rahmanzade R, Rahmanzadeh R, Tabarsi P, Hashemian SM. Noninvasive Versus Invasive Ventilation in COVID-19: One Size Does Not Fit All Anesth Analg. 2020;131(2): e114-e115. doi: 10.1213/ANE.0000000000004943/

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19-Final report. N Engl J Med 2020; 383:1813-26 DOI: 10.1056/NEJMoa2007764/

Rubin D, Chan-Tack K, Farley J, Sherwat A. FDA approval of remdesivir—a step in the right direction. N Engl J Med 2020; 383:2598-2600 doi: 10.1056/NEJMp2032369/

Siddiqui SH, Sarfraz A, Rizvi A, Shaheen F, Yousafzai MT, Ali SA. Global variation of COVID-19 mortality rates in the initial phase. Osong Public Health Res Perspect. 2021;12(2):64-72. doi: 10.24171/j.phrp.2021.12.2.03/